Clinical Trial

Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)

Study acronym: PANDA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-06-22; most recent amendment 2024-11-24.
Status change: Not Yet Recruiting → Recruiting 2024-11-17
Trial Details
NCT Number NCT04444349
Lead Sponsor Nanjing Medical University
Collaborators: The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University
Conditions Cardiovascular Disease
Enrollment 500 participants
Start Date 2021-02-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-27